Claude

Web Research

The Bottom Line from the Web

Cigna is executing one of the most consequential business model pivots in managed care: dismantling the rebate-based PBM model at Express Scripts while simultaneously divesting its Medicare Advantage business and transitioning CEO leadership – all within a 12-month window. The web reveals that the FTC settlement in February 2026 mandating structural PBM changes, combined with near-term margin pressure from rebate-free client renewals, creates a 2026-2027 earnings air pocket that the market has already begun pricing in with a ~10% stock decline over six months, even as analysts overwhelmingly rate the stock a Strong Buy with 22% upside to consensus targets.

What Matters Most

1. FTC Settlement Forces Structural Overhaul of Express Scripts' PBM Model

In February 2026, Express Scripts reached a landmark settlement with the FTC resolving allegations it manipulated insulin pricing. The agreement requires Express Scripts to eliminate spread pricing, decouple rebates and fees from drug list prices, and relocate its group purchasing organization (Ascent) from offshore to the United States. No direct financial penalty was imposed, but the mandated business practice changes are sweeping.

The FTC settlement effectively ends Express Scripts' traditional PBM model. While management calls this a "clearing event," the required changes to spread pricing and rebate structures will pressure margins through 2027-2028 as the business transitions.

Source: FTC settlement details, NCPA analysis, Reuters

2. Rebate-Free PBM Model Creates Near-Term Margin Pressure

Cigna announced in October 2025 that Evernorth will adopt a rebate-free pharmacy benefit model. It takes effect in 2027 for fully insured lives (~2 million members) and becomes the standard offering for all PBM clients in 2028, though rebate arrangements remain available on request. Major client renewals with Prime Therapeutics, the U.S. Department of Defense, and Centene were completed at lower margins, prompting analyst target cuts averaging 5-8%.

Cigna expects 2026-2027 margin pressure from the rebate-free transition. Analysts at TD Cowen cut their target from $387 to $333 in November 2025. The average analyst target has declined from ~$370 to ~$338.

Source: Fierce Healthcare, Drug Channels, Benzinga

3. CEO Transition: Cordani to Retire, Evanko Takes Over July 1, 2026

David Cordani, CEO since 2009, will retire effective July 1, 2026 and become Executive Chair. Brian Evanko, current President and COO (and former CFO/Cigna Healthcare President), will succeed him. Total shareholder return under Cordani exceeded 750%. The board reaffirmed 2026 financial outlook alongside the announcement. The company also strengthened the Lead Independent Director role.

Smooth internal succession with no strategic shift signaled. Evanko is deeply familiar with the business having served as CFO and led Cigna Healthcare. Markets reacted calmly.

Source: PR Newswire, Forbes

4. Medicare Advantage Divestiture Completed, Sharpening Evernorth Focus

HCSC completed its $3.3 billion acquisition of Cigna's Medicare Advantage, Medicare Part D, and CareAllies businesses in March 2025. This removes Medicare regulatory risk from Cigna's profile and frees capital for Evernorth expansion, including the $3.5 billion investment in Shields Health Solutions (specialty pharmacy) announced September 2025.

The divestiture strategically repositions Cigna with lower government program exposure than peers UnitedHealth and Humana. Institutional investors favor the reduced Medicare risk.

Source: Healthcare Finance, Reuters on Shields

5. Medical Cost Ratio Rising, Driven by Individual/Family Plans

Cigna Healthcare's MLR climbed to 84.4% in FY2025 from 83.2% in FY2024, driven primarily by Individual and Family Plans (IFP) business and higher stop-loss costs. Q4 2024 was the nadir, with a 15.2% EPS miss versus consensus. The company guided to an MCR of 83.7%-84.7% for 2026. Stop-loss repricing actions are underway.

The IFP business has been a persistent drag on Cigna Healthcare margins. Higher-than-expected medical costs in stop-loss and ACA plans bear watching through 2026.

Source: Becker's, Insurance Business Mag

6. Evernorth Specialty Pharmacy: Biosimilar Tailwind Worth ~$100B Over 5 Years

CEO Cordani stated that approximately $100 billion in U.S. specialty drug spend will face biosimilar and generic competition over the next five years. Evernorth's Accredo specialty pharmacy delivered 14% adjusted revenue growth in 2025, with specialty scripts up 13% YoY. The $3.5 billion Shields Health Solutions investment deepens hospital-based specialty pharmacy capabilities.

Evernorth's specialty and care services segment is the growth engine. Biosimilar adoption is a structural, multi-year tailwind that distinguishes Cigna from pure insurance peers.

Source: Managed Healthcare Executive, PR Newswire Shields

7. Bernstein Upgrade to Outperform After PBM "Clearing Events"

On March 12, 2026, Bernstein upgraded Cigna to Outperform, citing the FTC settlement and rebate-free model announcement as "clearing events" that remove regulatory overhang. The consensus remains strongly bullish: 18 of 23 analysts rate it Strong Buy, with an average target of ~$338 (22% upside from the ~$278 share price as of April 9, 2026).

Avg Price Target

$338

Current Price

$278

Strong Buy Ratings

Hold Ratings

Source: CNN/TipRanks, Zacks, StockAnalysis

8. 2,000 Job Cuts in February 2026 (~3% of Workforce)

Cigna cut approximately 2,000 jobs globally by end of February 2026, concentrated in corporate functions including administration, compliance, claims processing, IT support, and middle management. The company cited "efficiency initiatives" and affected workers received severance and transition support. Employee morale is described as poor on Glassdoor, exacerbated by a return-to-office mandate for remote workers within 50 miles of an office.

Source: Becker's, Healthcare Finance News

9. AI Claims Denial Litigation Ongoing

A class action over Cigna's PxDx AI-based claims review algorithm was allowed to proceed in March 2025 by a U.S. District Court in California. ProPublica reporting alleged Cigna doctors were pressured to review cases too quickly. State legislatures are also introducing bills targeting AI-based claims denials.

AI claims denial litigation represents a reputational and potentially financial risk. The PxDx algorithm is alleged to have automatically denied medically necessary tests.

Source: PPI Benefits, Medical Economics

10. RICO Class Action Over PBM Fee Structures

A 2026 RICO class-action lawsuit alleges improper fee structures through offshore entities in the PBM industry. Additionally, a federal antitrust suit against Cigna, Aetna, and UnitedHealth involving repricing vendor Zelis was greenlit by a Massachusetts court on March 30, 2026, with providers alleging one claim was repriced down by more than 88%.

Source: Insurance Business Mag

Recent News Timeline

No Results

What the Specialists Asked

Insider Spotlight

No Results

Cordani's Legacy: David Cordani has led Cigna since 2009, overseeing the transformative Express Scripts acquisition and the pivot toward health services. Total shareholder return exceeded 750% under his tenure. His transition to Executive Chair (rather than full retirement) suggests continued strategic influence.

Succession Quality: Brian Evanko is one of the most well-prepared successors in managed care. He served as CFO (leading the Express Scripts integration finance), then as President/CEO of Cigna Healthcare, and most recently as President/COO overseeing all business lines. The dual CFO/operator background is unusual and signals strong financial discipline.

Governance Note: The board consolidated its standalone compliance committee in November 2025, redistributing oversight across other committees. This occurred while the company remains under a 5-year Corporate Integrity Agreement with HHS-OIG (through ~2028). No material governance red flags were identified, but the compliance committee consolidation during an active CIA is worth monitoring.

Industry Context

PBM Reform Accelerating at State and Federal Levels. More than half a dozen states introduced or enacted PBM legislation in 2025, targeting rebate transparency, spread pricing bans, and tighter licensing. The FTC's settlement with Express Scripts sets a federal precedent. Legislation pending in Congress would ban spread pricing in Medicaid, require 100% rebate pass-through to plan sponsors, and delink PBM compensation from drug prices in Medicare. The Big Three PBMs (CVS Caremark, Express Scripts, OptumRx) control ~80% of the market and face bipartisan scrutiny.

Biosimilar Wave Creates Winners. Approximately $100 billion in U.S. specialty drug spend will face biosimilar/generic competition over 5 years. This is a structural tailwind for PBMs and specialty pharmacies that can manage the transition. Cigna's Evernorth, with Accredo's dominant specialty pharmacy position, is among the best positioned.

Managed Care Valuations Compressed. The entire managed care sector has seen P/E compression, driven by regulatory uncertainty (PBM reform, Medicare Advantage rate cuts, AI claims denial scrutiny) and rising medical costs. Cigna trades at ~9x forward earnings versus historical averages in the mid-teens. The "Break Up Big Medicine Act" endorsed by Mark Cuban in March 2026 adds to political risk.

Amazon and Cost Plus Drugs as Emerging Threats. Amazon Pharmacy and Mark Cuban's Cost Plus Drugs continue to gain market awareness as transparent, low-cost alternatives. While still small in market share, their presence accelerates the pressure on traditional PBM economics and validates the industry's pivot toward transparency models.